The Trump administration is not finalizing a Biden-era provision that would expand coverage of anti-obesity drugs under Medicare and Medicaid, which has disappointed some healthcare leaders. The post Health Execs Criticize Trump Administration for Not Expanding Coverage of Obesity Drugs appeared first on MedCity News.
Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves disease, which stems from the immune system’s attack on the thyroid gland, is the startup’s lead disease target. The post Immunology Startup Merida Bio Unveils $121M and a Lead Program for Graves’ Disease appeared…
The in-home primary care service model is poised for rapid growth and transformation. However, there is more work to be done before the “Housepitalist” becomes a household word. The post The Next Evolution in Care Delivery: Key Barriers to Scaling In-Home Primary Care appeared first on MedCity News.
These recommendations on how to care for babies who fail newborn screenings offer valuable lessons for public health officials, clinicians, and families. The post Beyond Newborn Screening: Four Essential Factors in Congenital Disease Care appeared first on MedCity News.
Among the investor judges for the track at INVEST, scheduled for May 20-21 in Chicago are Raffi Boyajian, of Cigna Ventures; Jane Suh of Alley Corp; and Ed Weklar of Blue Cross and Blue Shield of North Carolina. The post Which AI Health Tech Startups Will Present at INVEST Pitch Perfect Contest appeared first on…
Healthcare leaders hope Dr. Oz supports Medicare Advantage, nutrition and telehealth as CMS administrator. The post What Issues Do Healthcare Leaders Want Dr. Oz to Tackle as CMS Administrator? appeared first on MedCity News.
Rhythm Pharmaceuticals drug Imcivree met the body mass index reduction goals of a Phase 3 test in hypothalamic obesity, an acquired form of obesity stemming from dysregulation of the MC4R pathway in the hypothalamus. The engineered peptide drug is already approved for two genetically driven types of obesity. The post Rhythm Pharma Drug Lowers BMI…
Walter Singleterry has worked as a member of the Environmental Services at Baptist Health Shelby Hospital for the last 14 years. Not long after after he was hired, Walter was promoted to cleaning patients’ rooms—a position he does not take lightly. Phyllis Thomas, a manager in the EVS department at Shelby Hospital, has worked at…
GSK is licensing an ABL Bio technology yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease. The post GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier…
If you’re still evaluating benefits the same way you did five years ago, you’re already behind. Here are some ways to get ahead. The post Six for ‘26: Top Concerns for Benefits Leaders Heading into 2026 Planning appeared first on MedCity News.